Mesenchymal GBM, on the other hand, is characterized by the activation of the NF-κB pathway, increased necrosis, and inflammation, as well as the expression of mesenchymal markers such as CHI3L1 and MET, all of which contribute to a poorer prognosis. The gene discussed is MET; the disease is glioblastoma.